Moderna, Inc. MRNA
We take great care to ensure that the data presented and summarized in this overview for Moderna, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRNA
View all-
Baillie Gifford & CO44.7MShares$6 Billion3.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA39MShares$5.25 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY25.4MShares$3.41 Billion0.06% of portfolio
-
State Street Corp Boston, MA14.5MShares$1.94 Billion0.07% of portfolio
-
Flagship Pioneering Inc. Cambridge, MA9.67MShares$1.3 Billion67.87% of portfolio
-
Theleme Partners LLP London, X07.32MShares$984 Million39.54% of portfolio
-
Geode Capital Management, LLC Boston, MA6.75MShares$907 Million0.07% of portfolio
-
Wellington Management Group LLP Boston, MA5.6MShares$753 Million0.11% of portfolio
-
Morgan Stanley New York, NY5.49MShares$738 Million0.05% of portfolio
-
Goldman Sachs Group Inc New York, NY3.93MShares$528 Million0.08% of portfolio
Latest Institutional Activity in MRNA
Top Purchases
Top Sells
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at MRNA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 18
2024
|
Afeyan Noubar |
SELL
Open market or private sale
|
Direct |
15,000
-0.13%
|
$2,010,000
$134.3 P/Share
|
Jun 17
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
15,000
-1.02%
|
$2,070,000
$138.16 P/Share
|
Jun 14
2024
|
Stephane Bancel Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
26,840
+0.49%
|
-
|
Jun 12
2024
|
Afeyan Noubar |
SELL
Open market or private sale
|
Direct |
15,000
-0.08%
|
$2,190,000
$146.92 P/Share
|
Jun 11
2024
|
Afeyan Noubar |
SELL
Open market or private sale
|
Indirect |
202,832
-1.05%
|
$30,019,136
$148.84 P/Share
|
Jun 10
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,178
-24.51%
|
$766,344
$148.09 P/Share
|
Jun 07
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,247
+19.39%
|
-
|
Jun 05
2024
|
Afeyan Noubar |
SELL
Open market or private sale
|
Direct |
15,000
-0.09%
|
$2,250,000
$150.66 P/Share
|
Jun 03
2024
|
James M Mock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
691
-9.6%
|
$96,740
$140.72 P/Share
|
Jun 03
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
339
-0.02%
|
$47,460
$140.72 P/Share
|
Jun 03
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
122
-1.11%
|
$17,080
$140.72 P/Share
|
May 31
2024
|
James M Mock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,326
+15.56%
|
-
|
May 31
2024
|
Stephen Hoge President |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+0.04%
|
-
|
May 31
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
232
+2.07%
|
-
|
May 29
2024
|
Afeyan Noubar |
SELL
Open market or private sale
|
Direct |
20,000
-0.13%
|
$2,880,000
$144.42 P/Share
|
May 29
2024
|
James M Mock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
183
-3.02%
|
$26,352
$144.5 P/Share
|
May 29
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
183
-1.67%
|
$26,352
$144.5 P/Share
|
May 29
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
341
-0.02%
|
$49,104
$144.5 P/Share
|
May 28
2024
|
James M Mock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
328
+5.14%
|
-
|
May 28
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
328
+2.91%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 79.4K shares |
---|---|
Other acquisition or disposition | 44.7K shares |
Exercise of conversion of derivative security | 77.8K shares |
Open market or private sale | 936K shares |
---|